Financial Performance - The company's operating revenue for Q1 2023 was RMB 2,058,913,113.43, representing a year-on-year increase of 16.15%[4] - The net profit attributable to shareholders of the listed company was RMB 172,934,924.85, up 25.59% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 188,552,713.22, reflecting a 44.34% increase year-on-year[4] - The basic earnings per share for the period was RMB 0.12, representing a 20.00% increase[4] - The weighted average return on equity was 2.26%, an increase of 0.18 percentage points[4] - The net profit for Q1 2023 was CNY 168,505,392.26, an increase of 20.5% compared to CNY 139,878,030.56 in Q1 2022[22] - The total comprehensive income for Q1 2023 was CNY 165,996,029.57, compared to CNY 139,775,078.82 in Q1 2022, an increase of 18.7%[22] - The total profit for Q1 2023 was CNY 177,182,403.86, an increase from CNY 129,224,930.94 in Q1 2022, representing a growth of approximately 37.06%[31] - The net profit for Q1 2023 reached CNY 148,538,126.97, compared to CNY 106,376,314.80 in Q1 2022, marking an increase of about 39.67%[31] Cash Flow - The net cash flow from operating activities was RMB 373,933,429.54, showing a significant increase of 269.74%[4] - The cash flow from operating activities netted CNY 373,933,429.54, significantly higher than CNY 101,134,514.53 in the previous year, marking a growth of 269.5%[24] - Cash flow from operating activities for Q1 2023 was CNY 1,152,043,927.65, significantly up from CNY 540,029,542.11 in Q1 2022, indicating a growth of approximately 113.33%[32] - The total cash inflow from operating activities in Q1 2023 was CNY 2,150,341,175.61, while cash outflow was CNY 998,297,247.96, resulting in a net cash flow of CNY 1,152,043,927.65[32] Assets and Liabilities - Total assets at the end of the reporting period were RMB 18,694,368,161.57, a 2.99% increase from the end of the previous year[5] - The total assets as of March 31, 2023, were CNY 18,694,368,161.57, compared to CNY 18,151,737,482.18 at the end of 2022, reflecting an increase of 3.0%[18] - The total liabilities increased to CNY 10,764,516,339.35 as of March 31, 2023, from CNY 10,406,116,493.24 at the end of 2022, marking a rise of 3.4%[17] - The total liabilities increased to CNY 8,429,117,242.25 in Q1 2023 from CNY 7,944,976,145.97 in Q4 2022, marking an increase of about 6.1%[29] - The company's total assets as of March 31, 2023, amounted to CNY 17,881,973,790.67, an increase from CNY 17,236,575,254.67 at the end of 2022[29] Operating Costs and Expenses - The total operating costs for Q1 2023 were CNY 1,791,603,923.39, up 13.4% from CNY 1,578,705,956.71 in Q1 2022[19] - The total operating expenses for Q1 2023 were CNY 1,915,233,073.00, compared to CNY 1,825,919,831.07 in the previous year, reflecting an increase of 4.9%[24] Research and Development - Research and development expenses for Q1 2023 were CNY 202,193,404.97, slightly down from CNY 217,360,827.03 in Q1 2022[19] - Research and development expenses decreased to CNY 89,062,323.41 in Q1 2023 from CNY 103,942,743.89 in Q1 2022, a reduction of about 14.4%[30] Market Strategy - The company plans to continue expanding its market presence and investing in new product development to drive future growth[19] Other Financial Metrics - The gross profit margin for Q1 2023 was approximately 13.0%, compared to 10.9% in Q1 2022[19] - The gross profit for Q1 2023 was CNY 616,191,891.56, up from CNY 518,773,151.52 in Q1 2022, indicating a gross margin improvement[30] - The company reported a foreign exchange loss of CNY 2,258,971.89 in Q1 2023, compared to a loss of CNY 50,234.73 in Q1 2022[22] Borrowings - The company raised CNY 1,430,000,000.00 through borrowings in Q1 2023, compared to CNY 1,005,085,600.00 in Q1 2022, indicating a growth of 42.2%[24] - The company received CNY 1,010,000,000.00 in cash from borrowings in Q1 2023, a significant increase from CNY 275,000,000.00 in Q1 2022, representing a growth of about 267.27%[32] Cash and Cash Equivalents - The company's cash and cash equivalents increased to CNY 1,728,714,585.72 as of March 31, 2023, from CNY 1,365,152,641.03 at the end of 2022, representing a growth of 26.7%[14] - The cash and cash equivalents at the end of Q1 2023 stood at CNY 1,695,549,488.10, slightly down from CNY 1,720,947,195.78 at the end of Q1 2022[25] - The ending balance of cash and cash equivalents as of Q1 2023 was CNY 953,478,680.20, compared to CNY 587,657,165.25 at the end of Q1 2022, indicating an increase of approximately 62.14%[32]

Financial Performance - The company's operating revenue for 2022 reached ¥8,265,744,793.28, representing a 24.42% increase compared to ¥6,643,573,143.13 in 2021[19]. - Net profit attributable to shareholders for 2022 was ¥1,167,758,749.48, a significant increase of 139.52% from ¥487,535,117.22 in 2021[19]. - The net profit after deducting non-recurring gains and losses was ¥1,153,066,098.54, showing an impressive growth of 1,839.98% compared to ¥59,437,076.89 in 2021[19]. - The weighted average return on equity increased to 16.55% in 2022, up by 9.12 percentage points from 7.43% in 2021[20]. - The company reported a net cash flow from operating activities of ¥1,242,693,126.90, which is a 32.42% increase from ¥938,429,830.68 in 2021[19]. - The total assets at the end of 2022 were ¥18,151,737,482.18, reflecting a 17.35% increase from ¥15,468,124,894.16 at the end of 2021[19]. - Basic earnings per share for 2022 were ¥0.81, a 138.24% increase from ¥0.34 in 2021[20]. - The company achieved a record revenue of 8,265.74 million yuan in 2022, representing a year-on-year growth of 24.42%[27]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, reached 1,153.07 million yuan, a significant increase of 1,839.98% year-on-year[27]. Dividend Distribution - The company plans to distribute a cash dividend of 2.4 CNY per 10 shares, which represents 30.27% of the net profit attributable to ordinary shareholders for 2022[4]. - The total cash dividend amount for 2022 is 353,476,365.12 RMB, which represents 30.27% of the net profit attributable to ordinary shareholders in the consolidated financial statements[191]. - The total dividend amount, including share repurchase, is 403,496,311.07 RMB, accounting for 34.55% of the net profit attributable to ordinary shareholders[191]. Audit and Compliance - The company has received a standard unqualified audit report from Tianjian Accounting Firm for the fiscal year 2022[3]. - There are no non-operating fund occupations by controlling shareholders or related parties reported[6]. - The company has not violated decision-making procedures for providing guarantees[6]. - The company emphasizes the importance of risk awareness regarding forward-looking statements in its annual report[5]. - The company has not disclosed any significant changes in its registered address or office address during the reporting period[14]. - The company has confirmed that all board members attended the board meeting[3]. - The company has not faced any issues with more than half of the board members being unable to guarantee the authenticity of the annual report[7]. Market and Sales Performance - The company experienced a significant increase in sales volume due to the recovery of the market after the lifting of the FDA ban and the continuous expansion of its domestic formulation business[21]. - The company reported an increase in exchange gains due to the significant rise in the US dollar exchange rate, contributing to the overall profit increase[21]. - The domestic formulation sales maintained rapid growth, with an average annual compound growth rate exceeding 37.9% from 2020 to 2022[29]. - The company successfully won bids for three products in the seventh batch of national centralized procurement, enhancing market share and expanding the number of selected provinces[29]. - In the U.S. market, 31 out of 54 products had market shares ranking in the top three, with five products holding the number one position[28]. - Raw material sales grew by 18.67% year-on-year, with sales covering 106 countries and regions[30]. Research and Development - The company aims to enhance its research and development capabilities, with over 680 master's and doctoral talents currently on staff, covering various therapeutic areas[35]. - The company has established a comprehensive R&D capability covering biopharmaceuticals, chemical innovative drugs, cell therapy, generic drugs, and chemical raw materials, recognized as a national high-tech enterprise and a leader in the domestic pharmaceutical industry[42]. - The company has over 20 projects in its biopharmaceutical pipeline, with 11 projects currently in clinical trials, including a globally innovative dual-target anti-tumor drug project[44]. - The company has established eight major technology platforms, achieving breakthroughs in continuous flow and asymmetric synthesis technologies[32]. - The company invested a total of 120,190.72 million RMB in R&D during the reporting period, focusing on expanding its pipeline in biopharmaceuticals and small molecule new drugs[94]. Corporate Governance - The company adheres to corporate governance standards, ensuring independent operation of its board and committees, and has held 11 board meetings during the reporting period[155]. - The company has implemented a strict insider information registration management system, ensuring compliance with relevant laws and regulations to protect the rights of minority shareholders[157]. - The company’s governance structure complies with relevant laws and regulations, with no significant discrepancies noted in its governance practices[157]. - The company has established a long-term equity incentive mechanism to align employee interests with company development, promoting talent retention and governance improvement[157]. Strategic Initiatives - The company plans to continue expanding its domestic formulation business and capitalize on the recovery of the U.S. market following the FDA ban lift[62]. - The company aims to achieve a sales revenue of approximately 10 billion yuan in 2023, representing a year-on-year growth of about 20.98%[141]. - The company will focus on accelerating new product development and enhancing project management to expedite the market launch of new products[137]. - The company plans to deepen its global marketing system to enhance its competitive position in both international and domestic markets[138]. - The company is committed to improving its corporate governance structure and internal control mechanisms to enhance operational efficiency[146]. Risk Management - The company faces risks in new product development due to high technical difficulty, significant upfront investment, and lengthy approval cycles, which could adversely affect the recovery of initial investments if products fail to pass registration[147]. - The company is exposed to price volatility in raw materials, which could negatively affect financial performance; however, it is enhancing its core competitiveness by increasing the proportion of formulation business sales[151]. - Changes in industry policies could significantly impact market dynamics, operational models, and profitability if the company fails to adapt to regulatory adjustments[150]. Employee and Talent Management - The company has implemented a training program for employees, focusing on enhancing professional knowledge and leadership skills for management personnel[187]. - The company has a strategic approach to employee compensation, aligning with market levels and focusing on high-value positions[186]. - The company has a talent pool of over 100 high-level professionals with overseas backgrounds and 680 master's and doctoral talents, strengthening its R&D capabilities[54]. Environmental and Social Responsibility - The company invested approximately 303.76 million yuan in environmental protection during the reporting period[200]. - The management team emphasized a commitment to sustainability, aiming for a 50% reduction in carbon emissions by 2030[166].

Financial Performance - The company's operating revenue for Q3 2022 was ¥2,014,478,938.61, representing a year-over-year increase of 28.93%[4] - The net profit attributable to shareholders for Q3 2022 was ¥226,521,940.42, a significant increase of 206.26% compared to the same period last year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses for Q3 2022 was ¥254,881,436.49, reflecting a remarkable increase of 739.18% year-over-year[4] - The basic earnings per share for Q3 2022 was ¥0.16, up 166.67% from the previous year[5] - The diluted earnings per share for Q3 2022 was also ¥0.16, marking a 166.67% increase compared to the same period last year[5] - The net profit attributable to shareholders for the year-to-date period was ¥794,518,892.99, reflecting a year-over-year increase of 34.75%[4] - Net profit for the third quarter of 2022 was ¥804,387,508.78, representing a 35.4% increase compared to ¥594,079,162.20 in Q3 2021[19] - Total profit for Q3 2022 was ¥1,023,613,099.31, compared to ¥769,196,944.53 in Q3 2021, marking a 32.9% increase[18] Cash Flow and Investments - The net cash flow from operating activities for Q3 2022 was ¥108,087,994.93, a decrease of 59.41% year-over-year[4] - Cash flow from operating activities for the first three quarters of 2022 was ¥598,834,358.42, a decrease from ¥680,741,615.29 in the same period of 2021[21] - The net cash flow from investing activities was -$1,613,937,040.10, compared to -$1,511,070,936.81 in the previous year, indicating a decrease in investment cash flow[22] - The company reported a net cash outflow from investing activities of ¥956,918,578.56 in 2022, an improvement from a net outflow of ¥1,496,059,346.10 in 2021[28] Assets and Liabilities - Total assets at the end of Q3 2022 amounted to ¥16,891,397,134.24, an increase of 9.20% from the end of the previous year[5] - As of September 30, 2022, the company's total assets amounted to ¥16,891,397,134.24, an increase from ¥15,468,124,894.16 at the end of 2021, representing a growth of approximately 9.16%[14] - Total liabilities reached ¥9,546,520,932.79, compared to ¥8,691,800,745.73, representing an increase of about 9.84%[15] - Long-term borrowings rose to ¥2,632,241,900.00 from ¥1,827,315,850.00, indicating an increase of approximately 44.00%[15] - The company's equity attributable to shareholders increased to ¥7,102,584,007.77 from ¥6,558,842,119.10, reflecting a growth of about 8.30%[15] - Total liabilities reached $7,800,543,721.18, an increase from $7,168,420,297.17, representing a growth of approximately 8.8%[24] - The company's equity totaled $8,647,069,051.86, up from $7,977,024,920.80, indicating an increase of about 8.4%[25] Inventory and Receivables - The company's current assets totaled ¥7,196,597,436.74, compared to ¥6,812,609,308.04 in the previous year, indicating an increase of about 5.66%[12] - Accounts receivable rose to ¥2,317,403,765.50, up from ¥1,849,743,324.64, marking an increase of around 25.38%[12] - Inventory increased significantly to ¥3,285,899,939.60 from ¥2,738,528,577.05, which is an increase of approximately 20.00%[12] - The company’s inventory increased to $2,496,876,456.64 from $2,143,454,539.76, showing a rise of about 16.5%[23] Research and Development - Research and development expenses for Q3 2022 totaled ¥670,476,442.29, an increase of 17.6% from ¥570,006,180.69 in Q3 2021[18] - Research and development expenses increased to ¥299,112,514.85 in 2022, up 33.2% from ¥224,497,625.67 in 2021[26] Tax and Financial Expenses - The company reported a tax expense of ¥219,225,590.53 for Q3 2022, up from ¥175,117,782.33 in Q3 2021[18] - The company’s tax expenses increased to ¥95,069,094.01 in 2022 from ¥75,657,891.09 in 2021, reflecting a rise of 25.7%[27] - The company’s financial expenses showed a significant reduction, with a net financial expense of -¥158,826,268.73 in 2022 compared to ¥96,869,746.67 in 2021[26]

Financial Performance - The company's operating revenue for the first half of 2022 reached CNY 3,823,472,246, representing a 25.97% increase compared to CNY 3,035,289,790 in the same period last year[16]. - Net profit attributable to shareholders of the listed company was CNY 567,996,952.57, up 10.15% from CNY 515,655,364.88 in the previous year[16]. - The net profit after deducting non-recurring gains and losses surged by 223.83%, amounting to CNY 583,462,815.48 compared to CNY 180,173,599.74 in the same period last year[16]. - The net cash flow from operating activities was CNY 490,746,363.49, an increase of 18.40% from CNY 414,468,577.16 in the previous year[16]. - The total assets of the company at the end of the reporting period were CNY 16,171,802,694.24, reflecting a 4.55% increase from CNY 15,468,124,894.16 at the end of the previous year[16]. - The net assets attributable to shareholders of the listed company increased by 8.32% to CNY 7,104,322,942.53 from CNY 6,558,842,119.10 at the end of the previous year[16]. - Basic earnings per share for the first half of 2022 were CNY 0.39, an increase of 11.43% compared to CNY 0.35 in the same period last year[17]. - The diluted earnings per share were CNY 0.39, up 8.33% from CNY 0.36 in the previous year[17]. - The weighted average return on net assets increased by 0.69 percentage points to 8.30% from 7.61% in the previous year[17]. - The company reported a significant increase in the weighted average return on net assets after deducting non-recurring gains and losses, rising to 8.53% from 2.66% in the previous year, an increase of 5.87 percentage points[17]. Research and Development - The company has over 20 ongoing research projects in the biopharmaceutical sector, with 11 projects currently in clinical trials, including a globally innovative dual-target anti-tumor drug[19]. - The company has established a comprehensive R&D system, including a global registration center and multiple research institutes in China and the US[34]. - The company is committed to accelerating the development of biopharmaceuticals and innovative drugs as part of its strategic transformation[19]. - The company has a pipeline of nearly 40 small-scale research and reserve projects in active pharmaceutical ingredients (APIs), focusing on difficult and niche products[38]. - The company has successfully obtained MPP authorization for Pfizer's COVID-19 drug, enhancing its market presence[41]. Market Position and Strategy - The company has established stable partnerships with over 800 pharmaceutical companies globally, with product sales covering nearly 100 countries and regions[19]. - The company is a major global supplier of cardiovascular raw materials, particularly for the classes of drugs known as "prils" and "sartans"[19]. - The company has diversified its sales strategies in response to national healthcare reforms, focusing on market penetration and efficiency improvements[24]. - The company utilizes multiple sales models for its overseas products, including self-sales, cooperative sales, and agency sales[23]. - The global pharmaceutical market size approached $1.4 trillion in 2020, with a projected growth rate of 4%-5% in the coming years[27]. - North America and Europe account for over 62% of the global pharmaceutical market, with sales shares of 40% and 22% respectively, while China's market share has reached 20%[29]. Financial Management - The company reported a foreign exchange loss of CNY 3,816,701.65, compared to a loss of CNY 2,121,475.62 in the previous year[137]. - The company incurred a credit impairment loss of CNY 5,095,385.43, compared to a loss of CNY 3,215,670.21 in the previous year[138]. - The company reported a net investment loss of CNY 17,603,236.63 for the first half of 2022, a significant decline from a gain of CNY 87,366,579.03 in the previous year[135]. - The company has a dynamic procurement plan that adjusts based on production schedules and inventory levels, ensuring timely supply[20]. - The company has implemented lean management practices to enhance production efficiency and improve supply chain coordination[47]. Environmental and Compliance - The company is focused on enhancing safety production and environmental management, implementing various measures to ensure sustainable development[50]. - The company reported actual emissions of COD at 3.39 tons and ammonia nitrogen at 0.17 tons in the first half of 2022, within the approved limits[77]. - The company has implemented a thermal oxidation system for organic waste gas treatment, ensuring compliance with emission standards[81]. - The company completed environmental impact assessments for two projects, including a 500-ton annual production project for Levetiracetam and a 6 billion tablet solid preparation project[86]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[89]. Shareholder and Capital Management - No profit distribution or capital reserve increase is planned for the half-year period, with no dividends or stock bonuses proposed[74]. - The company granted 3.94544 million shares under the 2021 restricted stock incentive plan, with a grant date of April 25, 2022, at a price of 9.55 CNY per share[75]. - A total of 12.2285 million shares were repurchased and canceled due to reasons such as the departure of some incentive objects and unmet performance assessments[75]. - The company has established a dedicated repurchase account and completed the cancellation of shares on June 28, 2022[76]. - The company reported a total of 805.45 million yuan in investments for the current year across various projects[58]. Risk Management - The company highlighted risks associated with new product development, including long approval cycles and high upfront investments, which could adversely affect future returns[65]. - The ongoing national drug procurement policy is expected to further decrease average profit margins in the pharmaceutical industry, impacting the company's financial performance[67]. - The fluctuation risk of raw material prices is increasing due to intense competition in the raw material market, which could negatively impact the company's operating performance[71]. - The company is closely monitoring exchange rate fluctuations, as significant changes could impact revenue and profit levels due to its international business operations[71]. - The company is accelerating its globalization strategy, but geopolitical tensions and trade conflicts may adversely affect its export business[71].

Financial Performance - The company's operating revenue for 2021 was approximately ¥6.64 billion, representing a 2.44% increase from ¥6.49 billion in 2020[19]. - The net profit attributable to shareholders for 2021 was approximately ¥487.54 million, a decrease of 47.57% compared to ¥929.82 million in 2020[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥59.44 million, down 92.72% from ¥816.26 million in 2020[19]. - The operating cash flow for the year was approximately 938.43 million RMB, a decrease of 39.67% compared to the previous year[21]. - Basic earnings per share fell by 46.88% to 0.34 RMB, with diluted earnings per share also at 0.34 RMB[22]. - The company's total assets increased by 19.07% from the end of 2020, reaching approximately 15.47 billion RMB[21]. - The company's revenue in the pharmaceutical industry grew by 20.1% year-on-year, reaching CNY 2,928.85 billion in 2021[34]. - The gross profit margin for the main business decreased by 3.65 percentage points to 60.17%[59]. - The company achieved a net profit of approximately 2.05 billion RMB in Q4 2021, but reported a net loss of approximately 102.08 million RMB in the same quarter[24]. Research and Development - Research and development investment reached a new high, focusing on biopharmaceuticals, new drugs, and generics[22]. - The company has over 1,500 R&D personnel, with annual R&D investment exceeding 10% of sales[40]. - R&D expenses increased by 66.57% to CNY 942.26 million, accounting for over 10% of sales[56]. - The company has established a comprehensive drug research and development platform, covering the entire lifecycle from antibody discovery to commercialization[51]. - The company initiated 11 biopharmaceutical research projects, with 5 clinical trial approvals received in 2021, enhancing long-term growth prospects[30]. - The company has a robust pipeline with multiple products in various clinical trial phases, including III phase trials for HOT-3010 targeting moderate to severe plaque psoriasis[92]. - The company is focused on expanding its product offerings in the oncology and autoimmune disease sectors, with several drugs in late-stage clinical trials[92]. Market and Sales - The sales revenue in key markets such as China, Southeast Asia, and the Middle East increased by over 50% year-on-year[28]. - Domestic formulation sales revenue increased by 38.08%, while foreign formulation sales decreased by 23.43%[58]. - The company has established a multi-channel marketing system in the U.S., covering 95% of major pharmaceutical purchasers[54]. - The company is actively expanding its domestic formulation market while maintaining a strong presence in international raw material markets[41]. - The company plans to establish high-end technology formulation R&D platforms over the next 3-5 years, including melt extrusion and soft capsule technologies[87]. Corporate Governance - The company maintains a robust governance structure, ensuring independence from its controlling shareholder and compliance with legal requirements[135]. - The company has implemented a complete insider information management system to prevent insider trading and protect minority shareholders' rights[138]. - The company respects and protects the legitimate rights and interests of stakeholders, including banks, creditors, employees, customers, suppliers, and consumers[137]. - The company has established a scientific performance evaluation system linking assessment results to employee salary levels and promotions[136]. - The company actively implements an equity incentive mechanism to align employee interests with company development, enhancing governance structure and operational sustainability[136]. Environmental Responsibility - The company has implemented measures to reduce carbon emissions, focusing on energy efficiency and the adoption of advanced technologies to replace outdated equipment[188]. - The company has established online monitoring systems at discharge points to ensure compliance with pollution discharge standards[181]. - The company is actively promoting green development and resource conservation as part of its corporate social responsibility initiatives[190]. - The company has not faced any administrative penalties related to environmental issues during the reporting period[185]. - The company reported actual wastewater emissions of 6.08 tons of COD and 0.30 tons of ammonia nitrogen in 2021, which are within the approved limits[175]. Strategic Initiatives - The company plans to focus on innovation and structural adjustments in products and business to meet health demands and ensure sustainable growth[123]. - The company is committed to balancing internal growth with external expansion strategies to enhance its market position[123]. - The company aims to achieve a sales revenue target of 8.5 billion yuan for 2022, focusing on enhancing market share and expanding sales channels[126]. - The company is actively pursuing external collaborations and investments to support its growth strategy and enhance its innovation capabilities[126]. - The company is enhancing its internal management and operational efficiency to ensure sustainable and healthy development in a complex market environment[125]. Financial Management - The company has implemented a strict internal control management system in accordance with relevant laws and regulations, continuously improving and optimizing internal control systems to ensure compliance and safeguard shareholder interests[169]. - The internal control audit report for 2021 was issued by Tianjian Accounting Firm, confirming the effectiveness of the internal control with a standard unqualified opinion[171]. - The company has developed a financial derivatives trading management system to enhance its internal control framework[169]. - The company reported a total fair value of financial assets at the end of the period amounting to ¥594,559,029.78, with trading financial assets contributing ¥530,715,377.13[110]. - The company’s cash and cash equivalents decreased by 15.17% to 1,876.30 million yuan, representing 12.13% of total assets[71].

Financial Performance - The company's operating revenue for Q1 2022 was RMB 1,772,607,601.98, representing an increase of 18.42% compared to the same period last year[4] - The net profit attributable to shareholders of the listed company was RMB 137,701,672.91, a decrease of 46.02% year-on-year[4] - The company's diluted earnings per share for the period was RMB 0.10, down 41.18% from the same period last year[4] - Net profit for Q1 2022 was CNY 139.88 million, a decrease of 46% from CNY 259.72 million in Q1 2021[17] - The total profit before tax was CNY 197.93 million, down from CNY 331.81 million in the same quarter of the previous year, representing a decline of 40.2%[17] - The total comprehensive income for Q1 2022 was CNY 139.78 million, down from CNY 260.17 million in the same period last year[18] Cash Flow - The net cash flow from operating activities was RMB 101,134,514.53, showing a significant increase of 56.38% compared to the previous year[4] - Cash flow from operating activities generated a net amount of CNY 101.13 million, compared to CNY 64.67 million in Q1 2021, reflecting a 56.4% increase[20] - Net cash flow from investing activities was -$557.99 million, compared to -$415.82 million in the previous period, indicating an increase in cash outflow[21] - Cash inflow from financing activities totaled $1.01 billion, up from $478.34 million year-over-year, reflecting a significant increase in borrowing[21] - Net cash flow from financing activities was $328.87 million, a turnaround from a negative $159.60 million in the previous period[21] - The net decrease in cash and cash equivalents was -$133.19 million, an improvement from -$510.41 million in the prior period[21] - The ending balance of cash and cash equivalents stood at $1.72 billion, compared to $1.69 billion at the end of the previous period[21] Assets and Liabilities - Total assets at the end of the reporting period were RMB 15,920,304,326.53, reflecting a 2.92% increase from the end of the previous year[5] - Current assets totaled CNY 6,886,761,651.71 as of March 31, 2022, compared to CNY 6,812,609,308.04 at the end of 2021, reflecting a slight increase[13] - Total liabilities increased to CNY 9,002,635,838.03 in Q1 2022 from CNY 8,691,800,745.73 in Q4 2021, reflecting a rise of 3.6%[15] - The company experienced a significant decrease in contract liabilities, which fell by 39.89% to RMB 40,101,810.94 due to reduced advance payments[7] Equity and Shareholder Information - The company’s total equity attributable to shareholders was RMB 6,697,648,842.25, an increase of 2.12% from the previous year[5] - The company reported a total of 98,103 common shareholders at the end of the reporting period[9] - The company's equity attributable to shareholders reached CNY 6,697,648,842.25 in Q1 2022, compared to CNY 6,558,842,119.10 in Q4 2021, an increase of 2.1%[15] Research and Development - Research and development expenses increased to RMB 217,360,827.03, up 41.88% year-on-year, driven by advancements in biopharmaceuticals and new drug projects[8] - Research and development expenses rose to CNY 217.36 million, up 42% from CNY 153.20 million in the same period last year[17] Inventory and Receivables - Inventory increased to CNY 2,918,279,685.85 in Q1 2022 from CNY 2,738,528,577.05 in Q4 2021, indicating a growth of 6.6%[13] - Accounts receivable stood at CNY 1,799,037,564.23 in Q1 2022, slightly down from CNY 1,849,743,324.64 in Q4 2021, a decrease of 2.7%[13]

Financial Performance - The company's revenue for Q3 2021 was approximately ¥1.56 billion, a decrease of 0.17% compared to the same period last year[4]. - Net profit attributable to shareholders for Q3 2021 was approximately ¥73.96 million, down 71.79% year-on-year[4]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately ¥30.37 million, a decline of 87.55% compared to the previous year[4]. - The company reported a basic earnings per share of ¥0.06 for Q3 2021, a decrease of 66.67% year-on-year[5]. - Total operating revenue for the first three quarters of 2021 was ¥4,597,707,821.05, a decrease of 5.6% compared to ¥4,870,611,930.68 in the same period of 2020[16]. - Net profit for Q3 2021 was ¥594,079,162.20, down 33.1% from ¥887,035,750.65 in Q3 2020[19]. - Total profit for Q3 2021 was ¥769,196,944.53, a decrease of 28.1% from ¥1,069,067,651.80 in Q3 2020[19]. - The total comprehensive income for Q3 2021 was ¥590,541,445.18, down from ¥882,685,639.25 in Q3 2020, indicating a decline of 33.0%[20]. Assets and Liabilities - Total assets at the end of the reporting period were approximately ¥14.77 billion, an increase of 13.68% compared to the end of the previous year[5]. - The company's current assets totaled CNY 6.80 billion, up from CNY 6.52 billion year-over-year, indicating an increase of about 4.3%[13]. - Total liabilities increased to CNY 7.80 billion from CNY 6.27 billion, which is an increase of approximately 24.2%[15]. - The company's equity attributable to shareholders reached CNY 6.80 billion, up from CNY 6.51 billion, representing a growth of about 4.4%[15]. - Long-term borrowings rose to CNY 1.76 billion, compared to CNY 1.33 billion, indicating an increase of approximately 32.3%[15]. - The total non-current assets amounted to CNY 7.96 billion, up from CNY 6.47 billion, reflecting an increase of approximately 23.1%[14]. Cash Flow - The cash flow from operating activities for the year-to-date period decreased by 41.73% to approximately ¥680.74 million[7]. - The net cash flow from operating activities was CNY 680,741,615.29, compared to CNY 1,168,273,782.69 in the previous year[23]. - The net cash flow from investing activities was -CNY 1,511,070,936.81, a decrease from -CNY 999,183,762.80 year-over-year[23]. - The net cash flow from financing activities was CNY 960,393,034.23, improving from -CNY 123,823,124.56 in the previous year[23]. - The total cash and cash equivalents at the end of the period amounted to CNY 2,300,573,132.55, up from CNY 1,462,124,386.42 year-over-year[23]. Expenses and Costs - Total operating costs increased to ¥4,268,571,031.99 in Q3 2021 from ¥3,828,686,002.08 in Q3 2020, representing an increase of 11.5%[17]. - Research and development expenses rose to ¥570,006,180.69 in Q3 2021, up 50.4% from ¥379,087,834.41 in Q3 2020[17]. - The company experienced a rise in sales expenses, which amounted to ¥879,140,906.93 in Q3 2021, compared to ¥790,928,654.01 in Q3 2020, marking an increase of 11.1%[17]. - The decline in profits was primarily due to a drop in raw material prices, increased raw material costs, and rising environmental protection expenses[7]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was not specified, but the largest shareholder held 24.51% of the shares[8]. - The company’s retained earnings increased to CNY 3.47 billion from CNY 3.18 billion, showing a growth of about 9.2%[15]. Investment Income - The company reported a significant increase in investment income, reaching ¥158,598,981.02 in Q3 2021, compared to a loss of ¥20,578,396.32 in Q3 2020[17]. Cash Management - The company received CNY 2,156,707,463.00 in cash from borrowings, compared to CNY 3,755,614,424.05 in the previous year[23]. - Cash paid for the repayment of debts was CNY 1,129,404,102.33, down from CNY 3,499,260,400.00 year-over-year[23]. - The cash inflow from investment activities totaled CNY 224,890,029.59, compared to CNY 42,189,809.20 in the previous year[23]. - The cash outflow for the acquisition of fixed assets was CNY 1,687,657,116.40, an increase from CNY 901,977,072.00 year-over-year[23]. - The impact of exchange rate changes on cash and cash equivalents was -CNY 27,199,094.89, compared to -CNY 71,921,493.67 in the previous year[23].

Financial Performance - The company's operating revenue for the first half of 2021 was ¥3,035,289,790.06, a decrease of 8.18% compared to the same period last year[14]. - The net profit attributable to shareholders for the first half of 2021 was ¥515,655,364.88, down 10.84% year-on-year[14]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥180,173,599.74, a significant decrease of 66.46% compared to the previous year[14]. - The net cash flow from operating activities was ¥414,468,577.16, representing a decline of 34.14% from the same period last year[14]. - Basic earnings per share for the first half of 2021 were ¥0.35, a decrease of 12.50% year-on-year[15]. - Diluted earnings per share for the first half of 2021 were ¥0.36, down 10.00% compared to the same period last year[15]. - The weighted average return on net assets was 7.61%, a decrease of 2.19 percentage points from the previous year[16]. - The company reported a significant drop in the basic earnings per share after deducting non-recurring gains and losses to ¥0.12, a decrease of 67.57% year-on-year[16]. - The company reported a total comprehensive income of CNY 516,225,462.66, compared to CNY 608,877,676.11 in the first half of 2020, a decrease of 15.16%[128]. Assets and Liabilities - The total assets at the end of the reporting period were ¥14,518,563,595.26, an increase of 11.76% compared to the end of the previous year[14]. - The net assets attributable to shareholders at the end of the reporting period were ¥6,753,151,012.79, up 3.69% from the previous year[14]. - As of the end of the reporting period, the company's cash and cash equivalents amounted to ¥2,750,534,280.58, representing 18.94% of total assets, an increase of 24.35% compared to the previous year[39]. - The company's inventory reached ¥2,639,887,898.16, accounting for 18.18% of total assets, with an increase of 11.46% year-over-year[39]. - The company's total liabilities amounted to 7.549 billion RMB, with current liabilities at 3.852 billion RMB and non-current liabilities at 3.697 billion RMB[118]. - The total liabilities reached ¥7,548,515,559.01, an increase from ¥6,266,663,758.42, marking a growth of around 20.4%[123]. Research and Development - The company has established a comprehensive R&D system with 1,307 R&D personnel and has undertaken 31 national-level technology projects and 78 provincial-level projects[30]. - The company’s R&D expenses increased by 55.53% year-on-year, amounting to approximately $358.79 million, primarily due to increased investment in new drug and biopharmaceutical projects[35]. - The company is committed to increasing R&D investment to explore and discover new technologies and products[56]. - The company is advancing its biopharmaceutical projects, including the initiation of Phase I clinical trials for a globally innovative dual-target anti-tumor drug[32]. Market and Sales - The company has established long-term partnerships with over 500 pharmaceutical companies globally, with product sales covering nearly 100 countries and regions[18]. - The company has been increasing its self-operated export ratio since obtaining self-operated import and export rights in 2000, focusing on regions like Europe, the US, Southeast Asia, and Latin America[24]. - The company launched 3 new products in the U.S. market during the reporting period, with several products ranking high in market share[32]. - The company expanded its sales team and actively analyzed market trends to capture opportunities in emerging markets such as Southeast Asia, the Middle East, and Brazil[32]. Environmental Compliance - The company emphasizes strict quality control due to increased regulatory scrutiny from FDA, EU, and WHO, enhancing its quality management system[56]. - The company is facing risks related to environmental regulations, requiring significant investments in safety and environmental protection measures[57]. - The company has implemented an online monitoring system for wastewater and air emissions to ensure compliance with environmental standards[74]. - The company has established a wastewater treatment facility that meets the standards before discharging into the municipal sewage treatment plant[70]. Financial Management - The company has not proposed any profit distribution or capital reserve transfer for the reporting period[62]. - The company has not reported any significant changes in the audit opinions from the previous annual report, indicating consistency in financial reporting[87]. - The company has not engaged in any significant asset acquisitions or disposals during the reporting period, reflecting a cautious approach to expansion[93]. - The company’s credit rating remains at AA, with a stable outlook as per the latest assessment by Shanghai New Century Credit Rating Agency[118]. Shareholder Information - The company’s share capital increased by 1,746 shares, resulting in a total of 1,454,609,793 shares post-adjustment[100]. - The top shareholder, Chen Baohua, holds 365,697,935 shares, representing 25.14% of the total shares[103]. - The company completed the issuance of 18,426,000 convertible bonds, raising a net amount of RMB 182,170.45 million after deducting issuance costs[111]. - The total number of ordinary shareholders was 67,464 as of the end of the reporting period[102]. Legal and Regulatory Matters - The company has ongoing litigation related to the valsartan impurity incident, with outcomes still uncertain, highlighting potential risks for investors[89]. - The company has not faced any major lawsuits or arbitration matters that were not disclosed in temporary announcements, maintaining a clean legal standing[88]. - The company’s vice president was warned by the Shanghai Stock Exchange for engaging in short-term trading of company shares, although no profits were made[90]. Strategic Initiatives - The company is exploring strategic partnerships and potential acquisitions to bolster its market position and product pipeline[54]. - The company plans to continue expanding its market share through strategic initiatives focused on enhancing business capabilities and market analysis[32]. - The company has actively explored e-commerce models to improve product accessibility in the market[25].